Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Biopharma Boards Count on Executives—Not Bankers—for Private-PIPE Financing Success Collabrity Analysis
VANCOUVER, BC — July 2025
Chart: Distribution of Biopharma Private-PIPE Rounds
New analysis from Collabrity, the Biotech Private-PIPE Company™, reveals a decisive trend: in nearly every major private biopharma financing over the past 18 months, company executives—not placement agents or investment banks—led the raise.
Collabrity examined 410 private biopharma financings of $15 million or more—through Seed, Series A-Z, and other private placement financing rounds—closed between January 2024 and June 2025. Private placements in private equity financing rounds that meet these criteria are defined as “Private-PIPEs”. All were drawn from the curated, quality-checked archive of the Collabrity Report which reports on biopharma financings and acquisitions every workday. Public company financings and crossover rounds leading to IPOs were excluded.
The results are striking:
“When it comes to Biopharma Private-PIPEs, it’s Executives 403, Bankers 7.”
• 98% of these financings were completed without the involvement of a placement agent, investment bank, or broker.
• Executives raised $34.4 billion, while bankers accounted for just $0.5 billion.
Debunking Two Myths in Biopharma Fundraising
This analysis gives the lie to two enduring misconceptions:
1. “I only need a placement agent.” In practice, all but a handful of zero-retainer bankers and placement agents closed Biopharma Private-PIPEs during the 18-month study period.
2. “I only need to pay on success.” 98% of successful private biopharma Boards retained proven CXO fundraisers—typically at $50K/month or more for salary + bonus—whose primary responsibility was raising capital.
Successful fundraisers – seasoned C-level executives with strong Private-PIPE track records – are the essential success factor. Collabrity draws executives of the same phenotype, known as Collabrity Executive Advisors (CEAs), from their ranks. The CEAs currently available through Collabrity have collectively raised over $1 billion in Biopharma Private-PIPEs.
Collabrity’s Model: Executive Advisor-Led, Compliantly Structured
Under the supervision of its associated broker-dealer Finalis LLC, Collabrity has pioneered a compliant and collaborative model that empowers elite executive fundraisers to assist with private biopharma capital raises.
Collabrity supports not only biopharma, but also diagnostics, devices, drug delivery, and AI-powered drug development and healthtech companies. The firm is unlocking an estimated $23 billion annual market opportunity in private biopharma capital raises alone.
About the Collabrity Report
The Collabrity Report powers the firm’s insights with curated, high-quality investment data focused exclusively on the biotech sector. It draws from AnNie Qi™, Collabrity’s proprietary AI + natural human intelligence investor database for qualifying investors, updated daily by the firm’s analysts. The Private-PIPE study was derived entirely from these internal, client-exclusive sources.
About Collabrity Inc.
The Biotech Private-PIPE Company™
Collabrity provides full-service fundraising and advisory solutions to private biotechs raising capital. The firm’s innovative model centers on continuity—ensuring that the individuals who assist in raising capital remain accountable for delivering value post-financing. Founder and CEO Christopher Lehman is a 30-year biotech veteran, proven CFO/CBO fundraiser, and FINRA-licensed investment professional (Series 82/79), with 28 transactions totaling over $950 million in announced value.
Media Contact:
Christopher Lehman
Founder & CEO, Collabrity Inc.
Email: chris@collabrity.com
Website: https://collabrity.com
This material has been prepared for information and educational purposes only, and it is not intended to provide, nor should it be relied on for tax, legal, or investment advice. You should consult with your own tax, legal, and financial professionals for your specific situation.
The views and opinions expressed in this article are those of the author and do not necessarily reflect the views or opinions of Finalis Securities, LLC.
Securities offered through Finalis Securities LLC Member FINRA/SIPC. Collabrity Inc and Finalis Securities LLC are separate, unaffliated entities.
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.